secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001558370-23-019708
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio: MB-106 achieves 100% complete response in follicular lymphoma in Phase 1/2
--------------------------------------------------------------------------------

- 100% complete response rate in 5 follicular lymphoma patients; 100% overall response in follicular and Waldenstrom macroglobulinemia.
- Favorable safety: no CRS > Grade 1, no ICANS; outpatient administration feasible.
- Complete responses seen in patients previously treated with CD19-targeted CAR-T therapy.
- Plan to finalize Phase 2 dose in early 2024; End-of-Phase 1 FDA meeting expected H1 2024.
- Registrational trial planned for relapsed/refractory WM with 58 patients; top-line data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023019708/0001558370-23-019708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023019708/tmb-20231211x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer